205 related articles for article (PubMed ID: 26787892)
1. Common BRAF(V600E)-directed pathway mediates widespread epigenetic silencing in colorectal cancer and melanoma.
Fang M; Hutchinson L; Deng A; Green MR
Proc Natl Acad Sci U S A; 2016 Feb; 113(5):1250-5. PubMed ID: 26787892
[TBL] [Abstract][Full Text] [Related]
2. The BRAF oncoprotein functions through the transcriptional repressor MAFG to mediate the CpG Island Methylator phenotype.
Fang M; Ou J; Hutchinson L; Green MR
Mol Cell; 2014 Sep; 55(6):904-915. PubMed ID: 25219500
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic regulation in human melanoma: past and future.
Sarkar D; Leung EY; Baguley BC; Finlay GJ; Askarian-Amiri ME
Epigenetics; 2015; 10(2):103-21. PubMed ID: 25587943
[TBL] [Abstract][Full Text] [Related]
4. In-depth genomic data analyses revealed complex transcriptional and epigenetic dysregulations of BRAFV600E in melanoma.
Guo X; Xu Y; Zhao Z
Mol Cancer; 2015 Mar; 14():60. PubMed ID: 25890285
[TBL] [Abstract][Full Text] [Related]
5. MAFG mediates CIMP in BRAF-mutant colorectal cancer.
Cancer Discov; 2014 Nov; 4(11):OF11. PubMed ID: 25367952
[TBL] [Abstract][Full Text] [Related]
6. c-Myc is Required for BRAF
Qu Y; Yang Q; Liu J; Shi B; Ji M; Li G; Hou P
Theranostics; 2017; 7(7):2092-2107. PubMed ID: 28656062
[No Abstract] [Full Text] [Related]
7. The BRAF(V600E) causes widespread alterations in gene methylation in the genome of melanoma cells.
Hou P; Liu D; Dong J; Xing M
Cell Cycle; 2012 Jan; 11(2):286-95. PubMed ID: 22189819
[TBL] [Abstract][Full Text] [Related]
8. Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma.
Kumar SM; Yu H; Edwards R; Chen L; Kazianis S; Brafford P; Acs G; Herlyn M; Xu X
Cancer Res; 2007 Apr; 67(7):3177-84. PubMed ID: 17409425
[TBL] [Abstract][Full Text] [Related]
9. B-Raf(V600E) cooperates with alternative spliced Rac1b to sustain colorectal cancer cell survival.
Matos P; Oliveira C; Velho S; Gonçalves V; da Costa LT; Moyer MP; Seruca R; Jordan P
Gastroenterology; 2008 Sep; 135(3):899-906. PubMed ID: 18602919
[TBL] [Abstract][Full Text] [Related]
10. Frequent silencing of RASSF1A via promoter methylation in follicular thyroid hyperplasia: a potential early epigenetic susceptibility event in thyroid carcinogenesis.
Brown TC; Juhlin CC; Healy JM; Prasad ML; Korah R; Carling T
JAMA Surg; 2014 Nov; 149(11):1146-52. PubMed ID: 25229773
[TBL] [Abstract][Full Text] [Related]
11. MAFG is a potential therapeutic target to restore chemosensitivity in cisplatin-resistant cancer cells by increasing reactive oxygen species.
Vera-Puente O; Rodriguez-Antolin C; Salgado-Figueroa A; Michalska P; Pernia O; Reid BM; Rosas R; Garcia-Guede A; SacristÁn S; Jimenez J; Esteban-Rodriguez I; Martin ME; Sellers TA; León R; Gonzalez VM; De Castro J; Ibanez de Caceres I
Transl Res; 2018 Oct; 200():1-17. PubMed ID: 30053382
[TBL] [Abstract][Full Text] [Related]
12. The CpG island methylator phenotype correlates with long-range epigenetic silencing in colorectal cancer.
Karpinski P; Ramsey D; Grzebieniak Z; Sasiadek MM; Blin N
Mol Cancer Res; 2008 Apr; 6(4):585-91. PubMed ID: 18403637
[TBL] [Abstract][Full Text] [Related]
13. BRAF V600E mutation-specific antibody: A review.
Ritterhouse LL; Barletta JA
Semin Diagn Pathol; 2015 Sep; 32(5):400-8. PubMed ID: 25744437
[TBL] [Abstract][Full Text] [Related]
14. Correlation between hypermethylation of the RASSF2A promoter and K-ras/BRAF mutations in microsatellite-stable colorectal cancers.
Park HW; Kang HC; Kim IJ; Jang SG; Kim K; Yoon HJ; Jeong SY; Park JG
Int J Cancer; 2007 Jan; 120(1):7-12. PubMed ID: 17013898
[TBL] [Abstract][Full Text] [Related]
15. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells.
Sumimoto H; Imabayashi F; Iwata T; Kawakami Y
J Exp Med; 2006 Jul; 203(7):1651-6. PubMed ID: 16801397
[TBL] [Abstract][Full Text] [Related]
16. IGFBP7 is a p53-responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype.
Suzuki H; Igarashi S; Nojima M; Maruyama R; Yamamoto E; Kai M; Akashi H; Watanabe Y; Yamamoto H; Sasaki Y; Itoh F; Imai K; Sugai T; Shen L; Issa JP; Shinomura Y; Tokino T; Toyota M
Carcinogenesis; 2010 Mar; 31(3):342-9. PubMed ID: 19638426
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.
Busam KJ; Hedvat C; Pulitzer M; von Deimling A; Jungbluth AA
Am J Surg Pathol; 2013 Mar; 37(3):413-20. PubMed ID: 23211290
[TBL] [Abstract][Full Text] [Related]
18. The homeobox gene MEIS1 is methylated in BRAF (p.V600E) mutated colon tumors.
Dihal AA; Boot A; van Roon EH; Schrumpf M; Fariña-Sarasqueta A; Fiocco M; Zeestraten EC; Kuppen PJ; Morreau H; van Wezel T; Boer JM
PLoS One; 2013; 8(11):e79898. PubMed ID: 24244575
[TBL] [Abstract][Full Text] [Related]
19. Somatic BRAF-V600E mutations in familial colorectal cancer.
Vandrovcova J; Lagerstedt-Robinsson K; Påhlman L; Lindblom A
Cancer Epidemiol Biomarkers Prev; 2006 Nov; 15(11):2270-3. PubMed ID: 17119056
[TBL] [Abstract][Full Text] [Related]
20. Increased cancer predisposition in family members of colorectal cancer patients harboring the p.V600E BRAF mutation: a population-based study.
Wish TA; Hyde AJ; Parfrey PS; Green JS; Younghusband HB; Simms MI; Fontaine DG; Dicks EL; Stuckless SN; Gallinger S; McLaughlin JR; Woods MO; Green RC
Cancer Epidemiol Biomarkers Prev; 2010 Jul; 19(7):1831-9. PubMed ID: 20570909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
